-
Study of the Exogenous Peptide Effect on the TGF-β1 Expression – A Risk Factor for the Hepatocellular Carcinoma Recurrence
Vadym Shypulin,
Oksana Stoliarova,
Volodymyr Konovalenko,
Oleksiy Tatskyy,
Gennadiy Didenko,
Sergii Konovalenko
Issue:
Volume 7, Issue 4, August 2019
Pages:
73-78
Received:
20 June 2019
Accepted:
22 July 2019
Published:
6 August 2019
Abstract: An article deals with the influence of the transforming growth factor beta-1 (TGF-β1) on the carcinogenesis of hepatic cells, as well as attention is given to the role of this factor in the hepatocellular carcinoma (HCC) progression. We monitored two groups of patients: in the treatment group, patients were administered cancer vaccine therapy and anti-relapse immune corrector Arecur® – a complex of exogenous peptides with anti-inflammatory, anti-infective and regenerating properties; in the reference group, patients were not administered immune corrector. The study showed that the cancer vaccine has a positive effect on the activity of T-cell immunity and interleukin-2 expression level. The result of the inclusion of anti-relapse immune corrector Arecur® in the patients’ management regimen was the reduction of TGF-β1 expression. The lower recurrence rate of HCC in the treatment group suggests that Arecur® may prevent possible recurrences and metastasis of HCC by limiting TGF-β1 expression. Future researches of anti-relapse immune correction regimens for patients with hepatic tumours may improve the therapeutic strategy and prevention of the disease progression in the long term. In addition, immune correction using exogenous peptides is likely capable of preventing the malignancy in patients with chronic hepatitis and liver cirrhosis.
Abstract: An article deals with the influence of the transforming growth factor beta-1 (TGF-β1) on the carcinogenesis of hepatic cells, as well as attention is given to the role of this factor in the hepatocellular carcinoma (HCC) progression. We monitored two groups of patients: in the treatment group, patients were administered cancer vaccine therapy and a...
Show More
-
Interest of the D-dimers Assay in the Medical Care of Thromboembolic Disease: Experience of the Hematology Laboratory of the Military Hospital Avicenne of Marrakech
Maryam Mouamin,
Asmaa Allali,
Ghali Boufrioua,
Jihane Belkhair,
Hicham Yahyaoui,
Mustapha Ait Amer,
Mohamed Chakour
Issue:
Volume 7, Issue 4, August 2019
Pages:
79-83
Received:
22 June 2019
Accepted:
23 July 2019
Published:
10 August 2019
Abstract: The objective of our study is to show the benefits of D-dimers (DD) dosing in the diagnostic care of thromboembolic disease. A retrospective study conducted over a 2-year period (2016-2017), including all DD dosing requests sent to the hematology laboratory at the Avicenne Military Hospital, excluding patients under 18 years of age. The quantitative assay was performed by an immunoturbidimetric method on STA Compact automaton, (STAGO), with STA®-Liatest® D-Di reagents with respect for the pre-analytical phase. We collected 100 samples over the study’s two year period. The requests mainly came from the emergencies and polyvalent intensive care unit. The clinical picture suggested a deep vein thrombosis in 56% of cases and pulmonary embolism in 44% of cases. The search was positive in 78% of cases. Sensitivity and negative predictive value were 100%. Specificity in the ambulatory population was 66.66% vs 28% in the hospital population and also decreased with age.
Abstract: The objective of our study is to show the benefits of D-dimers (DD) dosing in the diagnostic care of thromboembolic disease. A retrospective study conducted over a 2-year period (2016-2017), including all DD dosing requests sent to the hematology laboratory at the Avicenne Military Hospital, excluding patients under 18 years of age. The quantitativ...
Show More
-
Impact of the Meningococcal A Conjugate Vaccine Introduction in the African Meningitis Belt, 2010-2017
Issue:
Volume 7, Issue 4, August 2019
Pages:
84-92
Received:
8 July 2019
Accepted:
30 July 2019
Published:
16 August 2019
Abstract: Meningococcal meningitis remains a burden in the African meningitis belt. Before 2010, Neisseria meningitidis serogroup A (N. meningitidis A) was the predominant pathogen causing deathly epidemics. The meningococcal A conjugate vaccine (MACV, MenAfrivac®) protects against N. meningitidis A. It was introduced in 2010 into highest meningitis risk health districts. There was limited data on the effects of MACV, mainly on the degree of relationship between N. meningitidis A and the MACV immunization coverage. The purpose of this quantitative study was to assess the effectiveness of MACV from 2010 to 2017 in 21 out of 26 countries of the African meningitis belt. An interrupted time series design and nonprobability sampling were used. Secondary data issued from meningitis enhanced surveillance were retrieved from World Health Organization database. The social ecological model was used as a theoretical framework for this study. The binomial negative regression and Pearson’s Chi-Square tests were used. The study found that after the MACV introduction there were a high degree of relationship between N. meningitidis A and MACV immunization coverage (χ2 (1) = 11039.49, p = 0.000, Phi = 0.657, P=0.000), 99% decline of the risk of N. meningitidis A (RR 0.01, 95% CI 0.08-0.013), and 99.6% decline of risk of epidemic due to N. meningitidis A (RR 0.004, 95% CI 0.001-0.016). The study demonstrated that high MACV coverage and high-quality meningitis surveillance were pivotal to reduce the burden of meningococcal meningitis A epidemic in African meningitis belt. Based on the results of this study, it is recommended to development and manufacture an affordable multivalent polysaccharide conjugate vaccine against N. meningitis (A, C, W135, X, Y) and introduce in meningitis belt countries to eliminate meningococcal meningitis in Africa, to update the risk assessment of the meningitis status of Africa meningitis belt after the introduction of MenAfriVac®, to continue to improve meningitis enhanced surveillance, and improving public health policies on immunization and meningitis enhanced surveillance to ensure sustainable high immunization coverage of meningococcal vaccines and high quality of meningitis epidemic detection.
Abstract: Meningococcal meningitis remains a burden in the African meningitis belt. Before 2010, Neisseria meningitidis serogroup A (N. meningitidis A) was the predominant pathogen causing deathly epidemics. The meningococcal A conjugate vaccine (MACV, MenAfrivac®) protects against N. meningitidis A. It was introduced in 2010 into highest meningitis risk hea...
Show More
-
A Study to Assess the Significance of Urinary Collagen IV Excretion to Predict Preeclampsia in Early Pregnancy
Kaneez Fatema,
Fatema Jebunnesa,
Salima Akter,
Towhidul Alam Chowdhury,
Liaquat Ali
Issue:
Volume 7, Issue 4, August 2019
Pages:
93-98
Received:
7 November 2018
Accepted:
22 August 2019
Published:
10 September 2019
Abstract: It was a prospective study with a case control design. The purpose of the study was to measure the urinary collagens IV (U-coll IV) and microalbumin (MA) level in early pregnancy and to explore the role of excretion U-coll IV in prediction of preeclampsia (PE). A total number of 119 pregnant women at 10-14 weeks of pregnancy were selected on the basis of availability. MA by immunoturbidimetry assay and U-coll IV by enzyme immunoassay method were measured in these subjects and they were followed up to the term for the possible development of PE. MA was defined by albumin-creatinine ratio (ACR) above 32mg/g and high U-coll IV was defined by values above the cut-off point 2.74 ng/ml determined by the median value of the (controls). The data were analyzed by grouping the subjects who developed PE in later stages of pregnancy (the PE group) and those who did not develop PE in later stages (Control group). From the total subjects, 10 developed PE which shows a prevalence of about 8.4%. The PE group had higher value of ACR as compared to Control [ACR, mg/g, median (range), 42.3]. The sensitivity of ACR in predicting PE was 80%, specificity 49.54%, PPV 12.69% and NPV 96.42% respectively. The sensitivity of high U-coll IV in predicting PE was 70%, specificity 50.5%, PPV 11.5% and NPV 94.8%. It may be concluded that early pregnancy levels of MA and U-coll IV can be used as predictors of PE with high negative predictive value; and U-coll IV has no added advantage over MA in this respect.
Abstract: It was a prospective study with a case control design. The purpose of the study was to measure the urinary collagens IV (U-coll IV) and microalbumin (MA) level in early pregnancy and to explore the role of excretion U-coll IV in prediction of preeclampsia (PE). A total number of 119 pregnant women at 10-14 weeks of pregnancy were selected on the ba...
Show More
